Open Access

Sex differences in the aging pattern of renin–angiotensin system serum peptidases

  • A. Fernández-Atucha1,
  • A. Izagirre2,
  • A. B. Fraile-Bermúdez1,
  • M. Kortajarena1,
  • G. Larrinaga1,
  • P. Martinez-Lage2,
  • E Echevarría3, 4 and
  • J. Gil3, 4Email author
Biology of Sex Differences20178:5

https://doi.org/10.1186/s13293-017-0128-8

Received: 24 September 2016

Accepted: 31 January 2017

Published: 3 February 2017

Abstract

Background

Serum peptidases, such as angiotensin-converting enzyme (ACE), angiotensin-converting enzyme-2 (ACE2), neutral endopeptidase (NEP), aminopeptidase N (APN), and aminopeptidase A (APA), are important elements of the renin–angiotensin system (RAS). Dysregulation of these enzymes has been associated with hypertension and cardiovascular risk. In the present study, serum activities of RAS peptidases were analyzed to evaluate the existence of sexual differences, with a possible different pattern in pre- and post-andropausal/post-menopausal participants.

Methods

One hundred and eighteen healthy men and women between 41 and 70 years of age (58 women and 60 men) were recruited to participate in the study. Serum RAS-regulating enzymes were measured by spectrofluorimetry. Enzymatic activity was recorded as units of enzyme per milliliter of serum (U/mL).

Results

Significantly lower serum APA activity was observed in men with respect to women; no sex differences were detected for ACE, ACE2, NEP, or APN. Significantly lower APA and ACE serum activity were observed in older men compared to older women. In contrast, younger (<55 years) men had significantly higher values of NEP serum activity than younger women. Significantly lower ACE serum activity was detected in older men compared to younger men. In women, significantly higher ACE2 serum activity was observed in older women compared to younger women.

Conclusions

These results suggest a differential effect of aging on the activity of RAS enzymes in men and women, especially with respect to the breakpoint of andropausia/menopausia, on the critical serum enzymatic activities of the RAS, which could correlate with sexual differences in cardiovascular risk.

Keywords

Sex differencesRenin–angiotensin systemSerum peptidasesAging

Background

The renin–angiotensin system (RAS) has been classically described as a circulating hormone system that regulates hydroelectrolytic balance and cardiovascular function [1]. The better-known bioactive peptide of RAS, angiotensin II, is produced by the action of angiotensin-converting enzyme (ACE) and acts through AT1 receptors [1]. The use of ACE inhibitors and AT1 receptor blockers is the universally recognized first-line strategy in the treatment of hypertension and cardiovascular disease [2].

Over the past 25 years, the classic understanding of RAS has undergone an extensive revision [3, 4]. The activities of different angiotensin-converting peptidases have been shown to produce several angiotensins that counterbalance the action of Ang II [1]. Further, several organs, tissues, and cells express all the components of RAS [5]. These local and intracellular RAS can regulate long-term biologic processes such as cell growth, proliferation, and tissue repair [1, 4, 5].

The newly expanded view of RAS describes endocrine, paracrine, autocrine, and intracrine functions and demonstrates that this peptidergic system regulates more diverse physiological phenomena than previously described [1, 4]. Moreover, the imbalance of RAS components has been associated with several chronic pathologies that go beyond cardiovascular and renal diseases [6], including proliferative (such as cancer) [7, 8] and degenerative disorders of the central nervous system (such as Alzheimer’s disease) [9, 10]. These diseases are primarily responsible for morbidity and mortality of adults in Western countries [1113]. For this reason, there is great utility for RAS-modulating drugs and application of RAS components as diagnostic/prognostic biomarkers of chronic diseases [4, 7, 9, 14, 15].

Experimental evidence suggests an important influence of gonadal hormones on RAS, which could explain, in part, sex differences in arterial pressure and in the onset of cardiovascular diseases [3, 16]. Studies in animal models have shown that the expression of angiotensin-converting enzymes is regulated by estrogens and testosterone in several tissues [16]. These peptidases can be secreted to the extracellular space from several different tissues [17], and gender differences are reflected in body fluids [10]. Studies performed in children and young adults have described basal activity of ACE, as well as the maximum ACE inhibition after enalapril treatment, and found that they are significantly lower in women than in men, suggesting that estrogens and androgens could affect serum soluble ACE activity and lead to sexual differences in blood pressure [18]. Therefore, sex differences should be considered in the study of RAS components and the search for new serum biomarkers.

Here, we describe the activity of five crucial angiotensin-regulating peptidases (ACE, ACE2, aminopeptidase A (APA), aminopeptidase N (APN), and neutral endopeptidase (NEP) [1] in the serum of adult men and women. In our study, male and female individuals were described as good models of normal health and considered to be “control” subjects for chronic diseases. All participants were between 41 and 70 years old (typically, this is the age of onset of several cardiovascular and proliferative disorders and early stages of neurodegenerative diseases [1113]), did not have any chronic pathology, and were not under any pharmacological treatment. Using this cohort, we sought to detect sex differences in RAS peptidase serum activity with aging.

Methods

Participants

Participants in this study comprised 118 healthy individuals with no history of any cardiovascular, proliferative, or central nervous system degenerative disease, ranging from 41–70 years old (60 males; age 56.58 ± 6.47 years; 58 females; age 54.47 ± 4.99 years). All participants underwent thorough medical examination, and we excluded all those who presented chronic pathologies involving drug treatment, such as estrogen replacement therapy, hormonal contraceptives or testosterone, or any significant neurologic, systemic, or psychiatric disorder that could cause cognitive impairment, as well as any who were pregnant or breastfeeding. All participants were informed of the extent of the study and signed an informed consent document approved by the Ethical and Scientific Committees (CEIC PGA-2).

Sample preparation

Blood samples (10 mL) were collected by venipuncture into heparinized tubes after fasting overnight. Following centrifugation (1500 rpm, for 10 min), serum samples were separated and stored frozen at −80 °C until the analysis of renin–angiotensin system enzyme activity.

Renin–angiotensin system-regulating enzyme activity

Enzyme activity in serum samples was measured by spectrofluorimetry in a microplate reader fluorometer FLUOstar OPTIMA (BMG Labtech). Angiotensin-converting enzyme (ACE/CD143: EC 3.4.11.1), angiotensin-converting enzyme 2 (ACE 2: EC 3.4.17.23), aminopeptidase A (APA/CD143: EC 3.4.11.7), aminopeptidase N (APN/CD13: EC 3.4.11.2), and neutral endopeptidase (NEP/CD10: EC 3.4.24.11) activity were measured. All samples were analyzed in triplicate and incubated at 37 ° C with their respective fluorogenic substrates in microplates for either 30 min (ACE, APA, APN, NEP/CD10) or 2 h (ACE2). Blanks were also included. The incubation times were based on preliminary assays to assess the linearity of the reaction over time as well as protein content. When introduced into the fluorimeter, specific emission and excitation filters for each substrate were selected. Each well was assayed with 10 flashes and the signals obtained were averaged. The value for the blank was discounted. The enzyme activity was expressed as units of enzyme activity per milliliter of serum (U/mL). One unit of activity is the amount of enzyme required to release 1 pmol of fluorescent product per minute. Specific inhibition assays for each substrate were performed to ensure appropriate measurement (86% or more inhibition accuracy was accepted).

ACE activity assay

Estimation of ACE activity was based on the fluorescence of the product generated upon hydrolysis by the enzyme of the substrate Abz-Gly-Phe(NO2) Pro (Bachem E2920). Fifty microliters of serum samples and 250 μL of substrate with 150 mM Tris-Hcl buffer, pH 8.3, plus 0.3 M NaCl were placed in a microplate reader and incubated as previously described. Excitation was at 355 nm and emission at 410 nm. The inhibition assay for ACE activity was performed with captopril (10 μM, Sigma).

ACE2 activity assay

The ACE2 activity assay was based on the fluorescence of the product generated upon hydrolysis by the enzyme of the substrate Abz-Ser-Pro-3-nitro-Tyr-OH (SPNPT; Bachem E2920). Reactions were initiated by adding 70 μL of the appropriate incubation mixture (substrate, 50 mM Tris-HCl buffer, pH 7.5, 2 μg BSA) to 30 μL of sample. After incubation, the fluorescence intensity was measured with an excitation filter at 355 nm and an emission filter at 410 nm. The inhibition assay for ACE2 activity was performed using DX600 (1 μM, Bachem).

APA and APN/CD13 activity assay

APA and APN/CD13 activity were measured using APA-β-naphthylamide as a substrate (Sigma N8381). Both were dissolved in 50 mM phosphate buffer. In the case of APA activity, 10 μL of serum were incubated with 190 μL of the mixture and 2 μg BSA, DTT, and CaCl2 were added to ensure that the reaction occurred. For APN activity, not only 2 μg of BSA but also the specific AlaAP inhibitor puromycin (40 μM) was added to discriminate between the AlaAP and APN/CD13 forms of total alanine aminopeptidase activity. Excitation was at 340 nm and emission at 410 nm. APA inhibition assay was performed using 1,10-phenanthroline (1,2 mM, Sigma) and APN/CD13 using leuhistin (0,05 mM, Sigma).

NEP/CD10 activity assay

The NEP/CD10 assay was performed by incubating 30-μL samples with 70 μL of a saturating concentration of N-dansyl-D-Ala-Gly-pNO2-Phe-Gly (DAGNPG, Sigma E39220). Captopril was added to discriminate between NEP activity and ACE forms. Excitation was at 340 nm and emission at 562 nm. NEP inhibition was performed using DL-thiorphan (Sigma).

Statistical analyses

To compare sexes, the female and male groups were each subdivided into two groups, separated by the median value of the sample. All reported values represent the median of the individual determination ± interquartile range (IQR). Statistical analysis was performed using SPSS® Statistics version 21. The Kolmogorov–Smirnov test was used to test the normality distribution of the data. A Mann–Whitney U test was performed to detect differences between the sexes, as well as between younger (<55 years) and older (≥55 years) participants when variables showed a non-normal distribution.

Linear regression models using systolic and diastolic blood pressures as dependent variables and enzyme activities as independent variables, as well as sex and age as independent variables of influence, were applied. Additionally, a linear regression analysis between age and renin–angiotensin system-regulating enzyme activities in women and men was performed.

Results

Descriptive parameters of 128 participants (all of them meeting inclusion criteria) are provided in Table 1. Men were found to have higher body mass indexes and higher blood pressure than women, as well as a lower body fat percentage. These differences were maintained among the specific age groups when a breakpoint of 55 years was selected to compare those less than or greater than 55 years of age (Table 2). A lack of changes in these parameters was observed in men when comparing the under 55 group to those over 55 years and in women over 55, presented a tendency toward higher systolic blood pressure (P = 0.078) compared to women under 55 years (Table 3).
Table 1

Descriptive statistics of the study population

 

WOMEN

MEN

Mann–Whitney U

Median

IQR

N

Median

IQR

N

Z

P value

Age (years)

54.97

6.34

58

55.76

10.18

60

−1.55

0.121

BMI (kg/m2)

23.45

4.15

58

25.65

3.83

60

−3.51

<0.001

Body fat (%)

30.70

11.95

58

20.61

10.53

60

−5.61

<0.001

SBP (mmHg)

120.5

21.5

58

130.1

21.5

60

−3.34

0.001

DBP (mmHg)

80

5.25

58

80

3.75

60

−2.57

0.010

Note: BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure

Table 2

Sex differences in BMI, body fat percentage, SBP, and DBP in younger (<55 years) and older (≥55 years) participants

  

WOMEN

MEN

Mann–Whitney U

Median

IQR

N

Median

IQR

N

Z

P value

< 55 years

BMI (kg/m2)

23.5

4.4

28

25.4

4.5

31

−2.336

0.020

Body fat (%)

30.1

14.9

28

20.2

10

31

−4.246

<0.001

SBP (mmHg)

120

13

28

130

19

31

−2.783

0.005

DBP (mmHg)

78.5

7

28

80

8

31

−0.005

0.047

> 55 years

BMI (kg/m2)

23.35

3.8

30

26.2

3.9

29

−2.664

0.008

Body fat (%)

31.15

9.6

30

20.7

10.8

29

−3.735

0.000

SBP (mmHg)

127

21

30

135

23

29

−1.803

0.071

DBP (mmHg)

80

5

30

80

0

29

−1.683

0.092

Note: BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure

Table 3

Effects of age (breakpoint >55 years) on BMI, body fat percentage, SBP, and DBP in all participants

  

< 55 years

> 55 years

U Mann–Whitney

Median

IQR

N

Median

IQR

N

Z

P value

WOMEN

BMI (kg/m2)

23.5

4.4

28

23.35

3.8

30

−0.537

0.591

Body fat (%)

30.1

14.9

28

31.15

9.6

30

−0.265

0.791

SBP (mmHg)

120

13

28

127

21

30

−1765

0.078

DBP (mmHg)

78.5

7

28

80

5

30

−0.459

0.646

MEN

BMI (kg/m2)

25.4

4.5

31

26.2

3.9

29

−0.059

0.953

Body fat (%)

20.2

10

31

20.7

10.8

29

−0.792

0.429

SBP (mmHg)

130

19

31

135

23

29

−1297

0.195

DBP (mmHg)

80

8

31

80

0

29

−0.182

0.856

Note: BMI Body mass index, SBP Systolic blood pressure, DBP diastolic blood pressure

ACE, ACE2, NEP, APN, and APA serum enzymatic activities were measured in men and women (Table 4). Significantly lower serum APA activity levels were observed in men with respect to women; no changes were observed for ACE, ACE2, NEP, or APN.
Table 4

Renin–angiotensin system-regulating enzyme activities and sex differences

 

TOTAL

WOMEN

MEN

Mann–Whitney U

Median

IQR

N

Median

IQR

N

Median

IQR

N

Z

P value

ACE

783.3

253.31

118

820.3

253.32

58

771.3

254.27

60

−1.281

0.2

ACE2

64.33

21.59

118

64.66

18.49

58

63.12

27.14

60

−0.350

0.726

NEP

15702

1724.59

118

15594

1272.12

58

15846

1974.44

60

−1.066

0.286

APN

10260

5417.84

118

10238

599.2

58

10436

4937.59

60

−0.711

0.477

APA

4143

1296.75

118

4345

1225.79

58

3946

991.35

60

−2.153

0.031

Note: ACE angiotensin-converting enzyme, ACE2 angiotensin-converting enzyme-2, NEP neutral endopeptidase, APN aminopeptidase N, APA aminopeptidase A

Values are medians of peptidase activity recorded as pmol of units of peptidase (UP) per milliliter of serum

When we compared serum enzymatic activities separately in younger and older participants (breakpoint 55 years) (Table 5), significantly lower ACE and APA serum activity levels were observed in men with respect to women, but without changes in ACE2, NEP, or AP. However, in the case of younger participants, significantly higher NEP serum enzymatic activity was observed in men than in women, but without changes in ACE, ACE2, APN, or APA. In contrast, in the case of older participants, significantly lower ACE and APA serum activity was observed in men than in women, but without changes in ACE2, NEP, or APN.
Table 5

Sex differences in ACE, ACE2, NEP, APN, and APA serum activities in younger (<55 years) and older (≥ 55 years) participants

  

WOMEN

MEN

Mann–Whitney U

 

Median

IQR

N

Median

IQR

N

Z

P value

< 55 years

ACE

820.3

249.77

28

841.4

281.02

31

−0.728

0.467

ACE2

61.71

16.69

28

59.75

23.57

31

−0.032

0.975

NEP

15474

1187.55

28

16203

2030.32

31

−2.017

0.044

APN

9931

5046.74

28

11517

6916.75

31

−1.653

0.098

APA

4304

1225.79

28

4281

1633.4

31

−0.121

0.903

> 55 years

ACE

815.9

272.13

30

744.4

201.43

29

−2.292

0.022

ACE2

71.11

16.22

30

70,05

30.92

29

−0.378

0.706

NEP

15703

1812.15

30

15344

1668.93

29

−0.562

0.574

APN

10238

6688.67

30

9973

4001.23

29

−0.577

0.564

APA

4361

1240.15

30

3820

623.97

29

−2.763

0.006

Note: ACE angiotensin-converting enzyme, ACE2 angiotensin-converting enzyme-2, NEP neutral endopeptidase, APN aminopeptidase N, APA aminopeptidase A

The effects of age, with a breakpoint of 55 years, on ACE, ACE2, NEP, APN, and APA serum activity was measured in all the participants, as well as separately in men and women (Table 6). Significantly lower ACE and a trend toward lower APA (P = 0.063) serum enzymatic activity was detected in older men, but without changes in ACE2, NEP, or APN. In women, significantly higher ACE2 serum activity was observed in older women, but with no changes in ACE, NEP, APN, or APA. To evaluate the statistical association between age and serum aminopeptidase activities, linear regression models were applied separately in women and men (Table 7). These analyses indicated a positive association between ACE2 serum activity and age in women. Accordingly, a linear regression model using systolic and diastolic blood pressure as dependent variables and enzyme activities as independent variables, as well as sex and age as independent variables of influence, showed that age, sex, and ACE2 influence systolic blood pressure, while only sex influences diastolic blood pressure, across the continuum of age (Table 8).
Table 6

Effects of age (breakpoint >55 years) on ACE, ACE2, NEP, APN, and APA serum activities in women and men

  

<55 years

≥ 55 years

Mann–Whitney U

Median

IQR

N

Median

IQR

N

Z

P value

WOMEN

ACE

820.3

249.77

28

815.9

272.13

30

−0.731

0.465

ACE2

61.71

16.69

28

71.11

16.22

30

−2.169

0.030

NEP

15474

1187.55

28

15703

1812.15

30

−0.965

0.335

APN

9931

5046.74

28

10238

6688.67

30

−0.747

0.455

APA

4304

1225.79

28

4361

1240.15

30

−0.327

0.744

MEN

ACE

841.4

281.02

31

744.4

201.43

29

−1.960

0.049

ACE2

59.75

23.57

31

70.05

30.92

29

−1.007

0.313

NEP

16203

2030.32

31

15344

1668.93

29

−1.013

0.311

APN

11517

6916.75

31

9973

4001.23

29

−1.620

0.105

APA

4281

1633.4

31

3820

623.97

29

−1.856

0.063

Note: ACE angiotensin-converting enzyme, ACE2 angiotensin-converting enzyme-2, NEP neutral endopeptidase, APN aminopeptidase N, APA aminopeptidase A

Table 7

Linear regression anaysis between age and renin–angiotensin system-regulating enzyme activities in women and men

  

B (95% CI)

β

R 2

P value

ACE

Women

5.979 (−5.408, 17.365)

0.139

0.019

0.297

Men

−6.139 (−14.206, 1.927)

−0.196

0.038

0.133

ACE2

Women

0.959 (0.323, 1.595)

0.38

0.145

0.004

Men

0.664 (−0.193, 1.521)

0.205

0.042

0.126

NEP

Women

14.87 (−48.08, 77.82)

0.063

0.004

0.638

Men

−52.80 (−105.2, −0.402)

−0.256

0.066

0.048

APN

Women

162.9 (−68.22, 394.1)

0.185

0.034

0.163

Men

−116.4 (−266.7, 33.78)

−0.2

0.040

0.126

APA

Women

51.75 (−16.21, 119.7)

0.2

0.040

0.133

Men

−29.23 (−72.52, 14.06)

−0.175

0.031

0.182

Note: ACE angiotensin-converting enzyme, ACE2 angiotensin-converting enzyme-2, NEP neutral endopeptidase, APN aminopeptidase N, APA aminopeptidase A

Table 8

Linear regression models including systolic blood pressure and diastolic blood pressure as dependent variables and enzyme activities as independent variables, as well as sex and age as independent variables of influence

Dependent variables

Predictors

B (95% CI)

β

R2

Adjusted R 2

SEE

P value

SBP

Model

  

0.478

0.228

15.263

<0.001

Age (years)

110.54 (47.06, 174.03)

0.304

   

0.001

Sex

−7.22 (−13.02,−1.43)

−0.221

   

0.015

ACE2

27.99 (3.19, 82.78)

0.194

   

0.027

Constant

−101.9 (−212.9, 9.22)

    

0.071

DBP

Model

  

0.225

0.051

6.685

<0.001

Sex

−3.06 (−5.55,−0.57)

−0.221

   

0.015

Constant

84.71 (80.78, 88.64)

    

<0.001

Note: SBP systolic blood pressure, DBP diastolic blood pressure, ACE2 angiotensin-converting enzyme-2

Discussion

Our results revealed sex differences in RAS serum enzymatic activities. Sex differences in soluble aminopeptidases, such as APA, have been described by other authors [19]. Moreover, it has been suggested that sex differences in blood pressure could be due to the effects of sex hormones on some of these peptidases, which are critical for the regulation of RAS [20]. In the present work, a critical range of age was selected for the inclusion of participants, all of whom were healthy middle-aged individuals, thus leading to a methodological improvement with respect to previous studies on this topic.

It has been proposed that sex differences in the regulation of arterial pressure by RAS could be due in part to a decrease in ACE serum activity in males, contrasting with a predominant ACE2 activity in females that could be lost in the post-menopausal period [16]. Sex differences in the incidence and evolution of cardiovascular disease and hypertension are also suggested to be due to the differential effects of sex steroids on critical components of RAS, which could possibly explain sex differences in blood pressure levels [21].

To detect specific physiological sex differences in the serum activities of RAS peptidases, we selected participants ranging from 41 to 70 years old, representing a period of time in which the onset of several cardiovascular and proliferative disorders and early stages of neurodegenerative diseases is most prevalent [1113], who did not have any chronic pathology, and were not under any pharmacological treatment. Consequently, this sample was intended to constitute a specific ideal model, to avoid bias caused by concomitant pathologies and/or medications.

Estrogen decrease, whereas testosterone increases, ACE activity, and consequently Ang II levels [20]. Accordingly, in our study, men aged ≥55 years showed a significantly lower ACE activity with respect to women. Further, among men, a significant reduction in ACE activity was observed in older participants (>55 years), with respect to younger ones (<55 years). These results suggest a greater influence on ACE activity by testosterone, compared to estrogens.

Post-menopausal changes in estrogen levels are well known [22], as a consequence of the physiological decline in ovarian follicle numbers [23], leading to sleep and body temperature disturbances in older women [24]. Although andropausia has been described as a controversial concept [25], it has been suggested that androgen deficiency in older men has been overlooked in clinical settings [26]. In 2006, the Massachusetts Male Aging Study (MMAS) described a reduction in testosterone levels in 21% of men aged 55–59 years, 26% of those aged 60–69 years, and 31% of those aged 70–86 years [27]. In fact, late-onset hypogonadism (age-related testosterone deficiency) has been recently recognized as a clinical syndrome associated with low testosterone levels and alteration of health status [28, 29], and the possibility that subclinical hypogonadism in andropausal men could be a physiologic response of the hypothalamus has been proposed [30]. The breakpoint of 55 years selected for comparisons between groups of age in our study is relevant to these findings.

Pre-menopausal women have lower blood pressure with respect to post-menopausal women [31] and pre-andropausal men [32], indicating that a difference in cardiovascular risk could be mediated by RAS. In fact, androgens can stimulate RAS [33], and the sexually dimorphic pattern of hypertension in the spontaneously hypertensive rat is androgen-dependent, rather than estrogen-dependent [34]. Accordingly, serum peptidases, such as ACE, ACE2, NEP, APN, and APA, which are important elements of the RAS, were studied here because dysregulation of these enzymes has been associated with hypertension and cardiovascular risk [35]. Our results revealed sexual differences in these activities, with a different pattern in pre- and post-andropausal/post-menopausal subjects.

Sex differences in APA activity were observed in the selected subjects. More precisely, a significantly lower serum activity of this enzyme was found in men than in women. These results suggest lower production of angiotensin III in men, which exerts an important physiological regulatory action on cerebral circulation [36]. However, a different pattern of sexual differences was observed in participants ≥55 years of age. In this group, significantly lower APA and ACE serum activities were observed in men compared to women. Considering that angiotensin III promotes increased blood pressure when injected intracerebroventricularly [37], and taking into account that it has been reported that inhibitors of APA, the enzyme that produces angiotensin III, can act as antihypertensive drugs [38, 39]; these results could help explain the smaller changes in blood pressure usually observed in post-andropausal men, with respect to that observed in post-menopausal women.

The reduction in APA activity may be linked to a decrease in the production of angiotensin III, leading to a reduction in cerebral vasoconstriction. This could prevent the elevation of cerebral blood pressure, thus contributing to the decrease in cerebrovascular risk found in post-andropausal men compared to post-menopausal women. However, in participants <55 years old, although significantly higher NEP and APN serum activities were observed, a lack of changes in ACE, ACE2, and APA serum activities was observed in men, with respect to women. Notably, reduced APA could be linked to higher levels of angiotensin II, thus tending to increase blood pressure. Further, elevated NEP in younger men could increase angiotensin 1-7, reducing this parameter.

With respect to aging, these serum enzymatic activities presented sex differences in the activity patterns when it was observed between younger (<55 years) and older (≥55 years) participants. Thus, higher ACE2 activity was found in older women, whereas lower ACE and APA activities were observed in older men. Due to the fact that ACE2 activity can increase production of angiotensin 1-7, which leads to vasodilatatory, antiproliferative, and antifibrotic effects [40], and considering that antithrombotic effects have been recently proposed for the ACE2-angiotensin (1-7)-Mas receptor axis [41], the increase in ACE2 activity in the post-menopausal period in women could lead to a differential cardiovascular risk in men and women [42].

Although post-menopausal women are known to have an increased cardiovascular risk, this fact does not necessary contradict the beneficial cardiovascular effects of the increase in ACE2 activity in older women. Thus, it cannot be discarded that the ACE2-ang1-7-Mas axis could counterbalance negative cardiovascular effects of other age-related mechanisms. Further studies are needed to detect angiotensin peptide changes induced by aging in both sexes.

A limitation of the study could be that we lack data regarding alcohol consumption, cigarette smoking status, or physical activity habits, additional information that could influence RAS activity. However, we must emphasize that in meeting our inclusion criteria, the participants did not have any chronic pathology and were not under any pharmacological treatment, making this a reasonably good sample for this study.

Conclusions

These results highlight sex differences in the aging pattern of renin–angiotensin system serum peptidases, suggesting a differential effect of aging in men, especially with respect to the breakpoint of andropausia, on the critical serum enzymatic activities of the RAS, which could correlate with sexual differences in cardiovascular risk.

Abbreviations

ACE: 

Angiotensin-converting enzyme

ACE2: 

Angiotensin-converting enzyme-2

APA: 

Aminopeptidase A

APN: 

Aminopeptidase N

BMI: 

Body mass index

BSA: 

Bovine serum albumin

CEIC: 

Comité ético de investigación clínica de Euskadi

DBP: 

Diastolic blood pressure

DTT: 

Dithiothreitol

IQR: 

Interquartile range

MMAS: 

Massachusetts Male Ageing Study

NEP: 

Neutral endopeptidase

RAS: 

Renin–angiotensin system

SBP: 

Systolic blood pressure

Declarations

Acknowledgements

We wish to thank Arantza Pérez and Juan Manuel Rodriguez Robledo and (UPV/EHU) for their technical contributions to this study.

Funding

This work was supported by a grant from the Basque Government (IT8-11/13), the University of the Basque Country UPV/EHU (UFI 11/44), and the Gangoiti-Barrera Foundation.

Availability of data and materials

The datasets collected and analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

GL and PM conceived the study, participated in its design and coordination, and helped to draft the manuscript. AI, ABF, and MK performed the experimental research, and EE and JG analyzed the data, created figures, and wrote the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Analyses for the studies were performed listed under affiliations. The authors certifies that the human protocol for this investigation was approved by the Ethical and Scientific Committees (CEIC PGA-2, Comité Ético de Investigación Clínica de Euskadi), and that all investigations were conducted in conformity with ethical principles of research, and that informed consent for participation in the study was obtained.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Nursing I, School of Nursing, University of the Basque Country (UPV/EHU)
(2)
Department of Neurology, CITA-Alzheimer Foundation
(3)
Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)
(4)
Department of Physiology, Faculty of Medicine, University of the Basque Country (UPV/EHU)

References

  1. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med. 2008;264:224–36.View ArticlePubMedGoogle Scholar
  2. Hamet P. The renin-angiotensin system: where do we stand, and what is the future? Am J Hypertens. 2005;18:125S–6.View ArticlePubMedGoogle Scholar
  3. Chappell MC, Marshall AC, Alzayadneh EM, Shaltout HA, Diz DI. Update on the angiotensin converting enzyme 2-angiotensin (1-7)-MAS receptor axis: fetal programing, sex differences, and intracellular pathways. Front Endocrinol (Lausanne). 2014;4:201. doi:10.3389/fendo.2013.00201.Google Scholar
  4. Romero CA, Orias M, Weir MR. Novel RAAS agonists and antagonists: clinical applications and controversies. Nat Rev Endocrinol. 2015;11:242–52.View ArticlePubMedGoogle Scholar
  5. Paul M, Mehr AP, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86:747–803.View ArticlePubMedGoogle Scholar
  6. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369:1208–19.View ArticlePubMedGoogle Scholar
  7. George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nature Rev Cancer. 2010;10:745–59.View ArticleGoogle Scholar
  8. Wegman-Ostrosky T, Soto-Reyes E, Vidal-Millán S, Sánchez-Corona J. The renin-angiotensin system meets the hallmarks of cancer. J Renin Angiotensin Aldosterone Syst. 2015;16:227–33.View ArticlePubMedGoogle Scholar
  9. Wright JW, Kawas LH, Harding JW. A role for the brain RAS in Alzheimer’s and Parkinson’s Diseases. Front Endocrinol (Lausanne). 2013;4:158. doi:10.3389/fendo.2013.00158.Google Scholar
  10. Puertas MC, Martínez-Martos JM, Cobo M, Lorite P, Sandalio RM, Palomeque T, et al. Plasma renin-angiotensin system-regulating aminopeptidase activities are modified in early stage Alzheimer’s disease and show gender differences but are not related to apolipoprotein E genotype. Exp Gerontol. 2013;48:557–64.View ArticleGoogle Scholar
  11. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe: epidemiological update. Eur Heart J. 2013;34:3028–34.View ArticlePubMedGoogle Scholar
  12. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.View ArticlePubMedGoogle Scholar
  13. Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, et al. Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol. 2016;15:455–532.View ArticlePubMedGoogle Scholar
  14. Larrinaga G, Blanco L, Sanz B, Perez I, Gil J, Unda M, et al. The impact of peptidase activity on clear cell renal cell carcinoma survival. Am J Physiol Renal Physiol. 2012;303:1584–91.View ArticleGoogle Scholar
  15. Sanz B, Perez I, Beitia M, Errarte P, Fernández A, Blanco L, et al. Aminopeptidase N activity predicts 5-year survival in colorectal cancer patients. J Investig Med. 2015;63:740–6.View ArticlePubMedGoogle Scholar
  16. Hilliard LM, Sampson AK, Brown RD, Denton KM. The “His and Hers” of the renin-angiotensin system. Curr Hypertens. 2013;15:71–9.View ArticleGoogle Scholar
  17. Rice GI, Jones AL, Grant PJ, Carter AM, Turner AJ, Hooper NM. Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension. 2006;48:914–20.View ArticlePubMedGoogle Scholar
  18. Zapater P, Novalbos J, Gallego-Sandín S, Hernández FT, Abad-Santos F. Gender differences in angiotensin-converting enzyme (ACE) activity and inhibition by enalaprilat in healthy volunteers. J Cardiovasc Pharmacol. 2004;43:737–44.View ArticlePubMedGoogle Scholar
  19. Martínez JM, Ramírez MJ, Prieto I, Alba F, Ramírez M. Sex differences and in vitro effects of steroids on serum aminopeptidase activities. Peptides. 1998;19:1637–40.View ArticlePubMedGoogle Scholar
  20. Ramírez-Expósito MJ, Martínez-Martos JM. Hypertension, RAS and gender: what is the role of aminopeptidases? Heart Fail Rev. 2008;13:355–65.View ArticlePubMedGoogle Scholar
  21. Maric-Bilkan C, Manigrasso MB. Sex differences in hypertension: contribution of the renin-angiotensin system. Gend Med. 2012;9:287–91.View ArticlePubMedGoogle Scholar
  22. Burger HG. The endocrinology of the menopause. Maturitas. 1996;23:129–36.View ArticlePubMedGoogle Scholar
  23. Burger HG, Hale GE, Robertson DM, Dennerstein L. A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women’s Midlife Health Project. Hum Reprod Update. 2007;13:559–65.View ArticlePubMedGoogle Scholar
  24. Murphy PJ, Campbell SS. Sex hormones, sleep, and core body temperature in older postmenopausal women. Sleep. 2007;30:1788–94.PubMedPubMed CentralGoogle Scholar
  25. Pines A. Male menopause: is it a real clinical syndrome? Climacteric. 2011;14:15–7.View ArticlePubMedGoogle Scholar
  26. Lee Y. Androgen deficiency syndrome in older people. J American Association Nurse Practitioners. 2014;26:179–86.View ArticleGoogle Scholar
  27. O’Donnell AB, Travison TG, Harris SS, Tenover JL, McKinlay JB. Testosterone, dehydroepiandrosterone, and physical performance in older men: results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2006;91:425–31.View ArticlePubMedGoogle Scholar
  28. Lunenfeld B, Mskhalaya G, Kalinchenko S, Tishova Y. Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men: a suggested update. Aging Male. 2013;16:143–50.View ArticlePubMedGoogle Scholar
  29. Lunenfeld B, Mskhalaya G, Zitzmann M, Arver S, Kalinchenko S, Tishova Y, Morgentaler A. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015;18:5–15.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Corona G, Maseroli E, Rastrelli G, Sforza A, Forti G, Mannucci E, Maggi M. Characteristics of compensated hypogonadism in patients with sexual dysfunction. J Sex Med. 2014;11:1823–34.View ArticlePubMedGoogle Scholar
  31. Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovasc Res. 2002;53:688–708.View ArticlePubMedGoogle Scholar
  32. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension. 2001;3:1199–208.View ArticleGoogle Scholar
  33. Kienitz T, Quinkler M. Testosterone and blood pressure regulation. Kidney Blood Press Res. 2008;31:71–9.View ArticlePubMedGoogle Scholar
  34. Chen YF, Meng QC. Sexual dimorphism of blood pressure in spontaneously hypertensive rats is androgen dependent. Life Sci. 1991;48:85–96.View ArticlePubMedGoogle Scholar
  35. Sánchez-Agesta Ortega R, de Saavedra-Alías JM A, Liébana-Cañada A, Sánchez-Muñoz B, Martínez-Martos JM, Ramírez-Expósito MJ. Circulating aminopeptidase activities in men and women with essential hypertension. Curr Med Chem. 2013;20:4935–45.View ArticlePubMedGoogle Scholar
  36. Bausback HH, Churchill L, Ward PE. Angiotensin metabolism by cerebral microvascular aminopeptidase A. Biochem Pharmacol. 1988;37:155–60.View ArticlePubMedGoogle Scholar
  37. Reaux-Le Goazigo A, Iturrioz X, Fassot C, Claperon C, Roques BP, Llorens-Cortes C. Role of angiotensin III in hypertension. Curr Hypertens Rep. 2005;7:128–34.View ArticlePubMedGoogle Scholar
  38. Bodineau L, Frugière A, Marc Y, Claperon C, Llorens-Cortes C. Aminopeptidase A inhibitors as centrally acting antihypertensive agents. Heart Fail Rev. 2008;13:311–9.View ArticlePubMedGoogle Scholar
  39. Marc Y, Llorens-Cortes C. The role of the brain renin-angiotensin system in hypertension: implications for new treatment. Prog Neurobiol. 2011;95:89–103.View ArticlePubMedGoogle Scholar
  40. Santos RA, Ferreira AJ, Simões e Silva AC. Recent advances in the angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis. Exp Physiol. 2008;93:519–27.View ArticlePubMedGoogle Scholar
  41. Fraga-Silva RA, Da Silva DG, Montecucco F, Mach F, Stergiopulos N, da Silva RF, Santos RA. The angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptor axis: a potential target for treating thrombotic diseases. Thromb Haemost. 2012;108:1089–96.View ArticlePubMedGoogle Scholar
  42. Campesi I, Occhioni S, Tonolo G, Cherchi S, Basili S, Carru C, Zinellu A, Franconi F. Ageing/menopausal status in healthy women and ageing in healthy men differently affect cardiometabolic parameters. Int J Med Sci. 2016;13:124–32.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement